Skip to main navigation
Skip to search
Skip to main content
OSU Center for Health Sciences Research Profiles Home
Help & Contact
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam, Vinay Prasad
Research output
:
Contribution to journal
›
Article
›
peer-review
963
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Patients with Cancer
100%
Checkpoint Inhibitors
100%
Checkpoint Inhibitor Immunotherapy
100%
Inhibitor Drug
75%
Demographic Characteristics
12%
Oncology
12%
United States
12%
Inclusion Criteria
12%
Patient Characteristics
12%
Metastatic Melanoma
12%
Publicly Available Data
12%
Ipilimumab
12%
Genome-driven Oncology
12%
Drug Label
12%
Tumor Subtype
12%
Cancer 2
12%
Metastatic Cancer
12%
Patients with Advanced Cancer
12%
U.S. Food
12%
Durable Response
12%
Retrospective Longitudinal Study
12%
Advanced or Metastatic
12%
Medicine and Dentistry
Immunotherapy
100%
Immunotherapy Drug
100%
Oncology
66%
Cross Sectional Study
33%
Biological Marker
33%
Neoplasm
33%
Metastatic Carcinoma
33%
Metastatic Melanoma
33%
Ipilimumab
33%
Demography
33%
Advanced Cancer
33%